Plain-English translation of NCT07361224 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether CLS-015, a new medication, can improve the results of CAR-T cell therapy for people with large B-cell lymphoma whose cancer isn't responding well during the initial treatment phase. CAR-T cell therapy is an advanced cancer treatment where your own immune cells are engineered to fight the lymphoma. The study is exploring whether this medication can help the CAR-T cells work better and reach the cancer more effectively.
About 4 in 10 patients with large B-cell lymphoma experience their cancer getting worse shortly after receiving CAR-T cell therapy, and many others see their cancer progress within the first year. This medication is being tested to help prevent that progression and improve outcomes for patients whose cancer isn't responding well during the early treatment period.
You likely qualify if…
You likely don't qualify if…
You would receive five infusions of the new medication (CLS-015) through an IV on specific days after your CAR-T cell infusion—on days 0, 3, 6, 10, and 15. You'll have frequent check-ups: daily blood tests and monitoring for the first 15 days, then twice weekly for another 15 days. After that, you'll have follow-up visits at 2, 6, 9, and 12 months to check how you're responding and watch for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Israel